{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:19:57Z","timestamp":1758759597725,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001786","name":"University of Adelaide","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.thromres.2019.07.016","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T11:23:12Z","timestamp":1563880992000},"page":"92-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Impaired adenylate cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y12 receptor antagonists"],"prefix":"10.1016","volume":"181","author":[{"given":"H.","family":"Imam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.B.","family":"Nooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-R.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.Y.","family":"Chirkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2019.07.016_bb0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/pgmj.75.888.591","article-title":"The role of coronary angioplasty and stenting in acute myocardial infarction","volume":"75","author":"Brodison","year":"1999","journal-title":"Postgrad Med J."},{"key":"10.1016\/j.thromres.2019.07.016_bb0010","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJM199912233412601","article-title":"Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group","volume":"341","author":"Grines","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","article-title":"Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial","volume":"391","author":"Al-Lamee","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2019.07.016_bb0020","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcin.2007.10.001","article-title":"Percutaneous coronary intervention for chronic stable angina","volume":"1","author":"Holmes","year":"2008","journal-title":"A Reassessment. JACC Cardiovasc Interv."},{"key":"10.1016\/j.thromres.2019.07.016_bb0030","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0035","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ncpcardio0602","article-title":"Drug insight: Clopidogrel nonresponsiveness","volume":"3","author":"Gurbel","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0045","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2019.07.016_bb0050","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0055","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.thromres.2015.03.011","article-title":"Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1\/adenylate cyclase signalling","volume":"136","author":"Hurst","year":"2015","journal-title":"Thromb Res."},{"key":"10.1016\/j.thromres.2019.07.016_bb0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/hrt.2010.220509","article-title":"Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting","volume":"97","author":"Bouman","year":"2011","journal-title":"Heart."},{"key":"10.1016\/j.thromres.2019.07.016_bb0065","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"Frelinger","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.vph.2013.10.002","article-title":"Clopidogrel \u201cresistance\u201d: pre- vs post-receptor determinants","volume":"59","author":"Hurst","year":"2013","journal-title":"Vascul Pharmacol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vph.2014.11.003","article-title":"Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia","volume":"65\u201366","author":"Nooney","year":"2015","journal-title":"Vascul Pharmacol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1146\/annurev.pharmtox.41.1.661","article-title":"Prostanoid receptors: subtypes and signaling","volume":"41","author":"Breyer","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10557-016-6671-4","article-title":"New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications","volume":"30","author":"Procter","year":"2016","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.thromres.2019.07.016_bb0090","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0100","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)60413-X","article-title":"Ischaemia versus bleeding: the art of clinical decision-making","volume":"373","author":"Stone","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2019.07.016_bb0110","first-page":"304","article-title":"The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes","volume":"49","author":"Worthley","year":"2007","journal-title":"Mediation by Superoxide Production, Resolution with Intensive Insulin Administration. J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0115","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/00005344-199506000-00015","article-title":"Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1","volume":"25","author":"Chirkov","year":"1995","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0120","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1160\/TH15-12-0981","article-title":"Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial","volume":"116","author":"Carreras","year":"2016","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.thromres.2019.07.016_bb0130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.amjmed.2014.11.007","article-title":"Reversal of hyperglycemia: effects on nitric oxide signaling","volume":"128","author":"Chong","year":"2015","journal-title":"Am J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0135","first-page":"1549","article-title":"Potent P2Y12 Inhibitors in Men Versus Women","volume":"69","author":"Lau","year":"2017","journal-title":"A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015241","volume":"7","author":"Venetsanos","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.thromres.2019.07.016_bb0145","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006922","article-title":"Can We Improve Long-Term Outcomes Postbifurcation Stenting by Prolonged Dual Antiplatelet Therapy?","volume":"11","author":"Horowitz","year":"2018","journal-title":"Circ Cardiovasc Interv."},{"key":"10.1016\/j.thromres.2019.07.016_bb0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2015.07.009","article-title":"Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy","volume":"242","author":"Siasos","year":"2015","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.thromres.2019.07.016_bb0155","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pharmthera.2007.06.012","article-title":"Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?","volume":"116","author":"Chirkov","year":"2007","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.thromres.2019.07.016_bb0160","first-page":"887","article-title":"Ramipril sensitizes platelets to nitric oxide","volume":"60","author":"Willoughby","year":"2012","journal-title":"Implications for Therapy in High-Risk Patients. J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2019.07.016_bb0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.thromres.2019.07.016_bb0170","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJMe0809422","article-title":"Refining the art and science of coronary stenting","volume":"360","author":"Ellis","year":"2009","journal-title":"N Engl J Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819303093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819303093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:39:39Z","timestamp":1758735579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384819303093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":34,"alternative-id":["S0049384819303093"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2019.07.016","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired adenylate cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y12 receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2019.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}